NO20091970L - Krystallmodifikasjoner av 3-(1,H-indol-3-yl)-4-[2-(4-metyl-piperazin-1-yl)-quinazolin-4-yl]-pyrrol-2,5-dion - Google Patents

Krystallmodifikasjoner av 3-(1,H-indol-3-yl)-4-[2-(4-metyl-piperazin-1-yl)-quinazolin-4-yl]-pyrrol-2,5-dion

Info

Publication number
NO20091970L
NO20091970L NO20091970A NO20091970A NO20091970L NO 20091970 L NO20091970 L NO 20091970L NO 20091970 A NO20091970 A NO 20091970A NO 20091970 A NO20091970 A NO 20091970A NO 20091970 L NO20091970 L NO 20091970L
Authority
NO
Norway
Prior art keywords
quinazolin
pyrrol
piperazin
indol
dione
Prior art date
Application number
NO20091970A
Other languages
English (en)
Norwegian (no)
Inventor
Piotr Karpinski
Paul Allen Sutton
Dimitris Papoutsakis
Stephanie Monnier
Elias Ndzie
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38921707&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20091970(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20091970L publication Critical patent/NO20091970L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20091970A 2006-10-20 2009-05-20 Krystallmodifikasjoner av 3-(1,H-indol-3-yl)-4-[2-(4-metyl-piperazin-1-yl)-quinazolin-4-yl]-pyrrol-2,5-dion NO20091970L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85338406P 2006-10-20 2006-10-20
PCT/US2007/022241 WO2008051440A1 (en) 2006-10-20 2007-10-18 Crystal modifications -3- (1h-ind0l-3-yl) -4- [2- (4-methyl-piperazin-1-yl) -quinazolin-4-yl] -pyrrole-2, 5-d ione

Publications (1)

Publication Number Publication Date
NO20091970L true NO20091970L (no) 2009-05-20

Family

ID=38921707

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091970A NO20091970L (no) 2006-10-20 2009-05-20 Krystallmodifikasjoner av 3-(1,H-indol-3-yl)-4-[2-(4-metyl-piperazin-1-yl)-quinazolin-4-yl]-pyrrol-2,5-dion

Country Status (23)

Country Link
US (1) US8865897B2 (es)
EP (1) EP2102195A1 (es)
JP (1) JP5302199B2 (es)
KR (1) KR20090073231A (es)
CN (2) CN103265533A (es)
AR (1) AR063491A1 (es)
AU (1) AU2007309558B2 (es)
BR (1) BRPI0717461A2 (es)
CA (1) CA2666965A1 (es)
CL (1) CL2007003006A1 (es)
EC (1) ECSP099344A (es)
IL (1) IL197962A (es)
MA (1) MA30886B1 (es)
MX (1) MX2009004048A (es)
MY (1) MY158026A (es)
NO (1) NO20091970L (es)
NZ (1) NZ576241A (es)
PE (1) PE20081133A1 (es)
RU (1) RU2481341C2 (es)
TN (1) TN2009000147A1 (es)
TW (1) TWI399374B (es)
WO (1) WO2008051440A1 (es)
ZA (1) ZA200902048B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2167493A1 (en) * 2007-03-09 2010-03-31 Novartis AG Salts of 3- (1h-ind0l-3-yl) -4- [2- (4-methyl-piperazin-i-yl) -quinazolin-4-yl]-pyrrole-2,5-di one
US9017528B2 (en) 2011-04-14 2015-04-28 Tel Nexx, Inc. Electro chemical deposition and replenishment apparatus
US9005409B2 (en) 2011-04-14 2015-04-14 Tel Nexx, Inc. Electro chemical deposition and replenishment apparatus
US9303329B2 (en) 2013-11-11 2016-04-05 Tel Nexx, Inc. Electrochemical deposition apparatus with remote catholyte fluid management

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100916613B1 (ko) 2000-11-07 2009-09-14 노파르티스 아게 단백질 키나제 ｃ 억제제로서의 인돌릴말레이미드 유도체
GB0504203D0 (en) * 2005-03-01 2005-04-06 Novartis Ag Organic compounds
WO2008155022A1 (en) 2007-06-18 2008-12-24 Sanofi-Aventis Pyrrole derivatives as p2y12 antagonists

Also Published As

Publication number Publication date
KR20090073231A (ko) 2009-07-02
MY158026A (en) 2016-08-30
ZA200902048B (en) 2010-01-27
TN2009000147A1 (en) 2010-10-18
US20100041884A1 (en) 2010-02-18
NZ576241A (en) 2012-05-25
WO2008051440A1 (en) 2008-05-02
CA2666965A1 (en) 2008-05-02
CL2007003006A1 (es) 2008-05-23
ECSP099344A (es) 2009-06-30
EP2102195A1 (en) 2009-09-23
PE20081133A1 (es) 2008-09-16
JP2010506927A (ja) 2010-03-04
MX2009004048A (es) 2009-04-27
IL197962A (en) 2013-08-29
CN101522664B (zh) 2013-06-12
RU2481341C2 (ru) 2013-05-10
TWI399374B (zh) 2013-06-21
BRPI0717461A2 (pt) 2013-10-08
IL197962A0 (en) 2009-12-24
US8865897B2 (en) 2014-10-21
CN103265533A (zh) 2013-08-28
AR063491A1 (es) 2009-01-28
MA30886B1 (fr) 2009-11-02
CN101522664A (zh) 2009-09-02
AU2007309558A1 (en) 2008-05-02
JP5302199B2 (ja) 2013-10-02
TW200829572A (en) 2008-07-16
RU2009118816A (ru) 2010-11-27
AU2007309558B2 (en) 2012-05-24

Similar Documents

Publication Publication Date Title
MX2022009998A (es) Formas cristalinas de la n-(4-(4-(ciclopropilmetil)piperazin-1- carbonil)fenil)quinolin-8-sulfonamida.
MX2009002229A (es) Benzotriazoles como moduladores de cinasas.
CY1113076T1 (el) Κρυσταλλικες μορφες του 4-μεθυλο-ν-[3-(4-μεθυλ-ιμιδαζολ-1-υλ)-5-τριφθορομεθυλο-φαινυλο]-3-(4-πυριδιν-3-υλ-πυριμιδιν-2-υλαμινο)-βενζαμιδιου
NO20084418L (no) Azolopyridin-3-on derivater som inhibitorer av endoteliallipase
NO20076066L (no) Oksadiazolderivater som DGAT-inhibitorer
RS54457B1 (en) CRYSTAL (R) - (E) -2- (4- (2- (5- (1- (3,5-Dichloropyridin-4-yl) ethoxy) -1H-indazol-3-yl) vinyl) -1H- PIRAZOL-1-IL) ETHANOL AND ITS USE AS FGFR INHIBITOR
EA201001005A1 (ru) Производные 2-бензилпиридазинона в качестве ингибиторов мет киназы
NO20082136L (no) 1,5-substituerte indol-2-yl-amidderivater
EA201070395A1 (ru) Ингибиторы polo-подобных киназ
EA201000093A1 (ru) Производные пиридазинона
ATE479687T1 (de) Kinaseinhibitoren
UY30639A1 (es) Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
TW200722421A (en) Azole derivatives as inhibitors of lipases and phospholipases
WO2008017361A3 (de) 2-(heterocyclylbenzyl)-pyridazinonderivate
RS53845B1 (en) OXADIAZOL DERIVATIVES AND THEIR USE AS A POTENTIAL OF METABOTROPIC GLUTAMATE RECEPTORS-842
MX2009012595A (es) Derivados de espiroindolinona.
EA200970019A1 (ru) Кристаллические формы 4-[2-(4-метилфенилсульфанил)фенил]пиперидина с объединенным ингибированием повторного поглощения серотонина и норадреналина для лечения невропатической боли
ATE542800T1 (de) Kinasehemmer und ihre anwendungsverfahren
WO2006037032A3 (en) Prodrugs of protein tyrosine kinase inhibitors
EA201000618A1 (ru) 5-цианотиенопиридины для лечения опухолей
NO20091970L (no) Krystallmodifikasjoner av 3-(1,H-indol-3-yl)-4-[2-(4-metyl-piperazin-1-yl)-quinazolin-4-yl]-pyrrol-2,5-dion
NO20083269L (no) Prosess for a anvende krystallinsk orlistatmetoder
NO20080034L (no) Benzotiazol-2-on derivater som lipase og fosfolipaseinhibitorer
WO2007087419A3 (en) Substituted 3-(5-membered unsaturated heterocyclyl) -1, 3-dihydro-indol-2-one derivatives as tyrosine kinase inhibitors for the treatment of cancer
EA201100941A1 (ru) Производные 3-(3-пиримидин-2-илбензил)-1,2,4-триазоло[4,3-b]пиримидина

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application